Q1 EPS Estimates for Myriad Genetics Cut by Leerink Partnrs

Myriad Genetics, Inc. (NASDAQ:MYGN) – Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Myriad Genetics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.18) per share for the quarter, down from their prior estimate of ($0.08). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.16) EPS.

A number of other equities analysts have also recently commented on MYGN. Morgan Stanley reduced their target price on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Bank of America reduced their price objective on Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research note on Friday, December 13th. Raymond James reaffirmed an “outperform” rating and set a $19.00 target price (down previously from $27.00) on shares of Myriad Genetics in a research note on Tuesday. UBS Group reduced their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Leerink Partners downgraded shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $22.14.

Myriad Genetics Trading Down 3.0 %

Shares of Myriad Genetics stock opened at $10.73 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics has a twelve month low of $9.76 and a twelve month high of $29.30. The firm has a market capitalization of $976.81 million, a PE ratio of -8.25 and a beta of 1.88. The firm’s 50-day moving average price is $13.28 and its 200 day moving average price is $19.04.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same period in the previous year, the company earned ($0.12) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd acquired a new position in shares of Myriad Genetics in the 3rd quarter valued at $32,000. Sterling Capital Management LLC lifted its position in Myriad Genetics by 829.9% in the fourth quarter. Sterling Capital Management LLC now owns 2,864 shares of the company’s stock valued at $39,000 after buying an additional 2,556 shares during the last quarter. KBC Group NV boosted its stake in Myriad Genetics by 132.8% during the fourth quarter. KBC Group NV now owns 5,845 shares of the company’s stock worth $80,000 after buying an additional 3,334 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after acquiring an additional 583 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. increased its position in shares of Myriad Genetics by 43.8% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after acquiring an additional 1,471 shares during the last quarter. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.